RESUMO
A 130,000 Mr protein was isolated from human platelets by sequential DEAE-Sephacel and Sepharose Cl-4B chromatography. Low shear viscometric measurements showed that the enriched protein after DEAE-Sephacel chromatography inhibited actin polymerization. This effect was somewhat greater in the presence of EGTA than in the presence of calcium. Further purification by Sepharose Cl-4B chromatography resulted in a complete loss of this inhibitory effect. Studies with fluorescent actin detected no nucleation or "+" end capping activity in either the DEAE-Sephacel- or Sepharose Cl-4B-purified vinculin. Antibodies raised in mice against the 130,000-mol-wt protein were shown to cross-react with chicken gizzard vinculin and a similar molecular weight protein was detected in WI38 cells and, Madin-Darby canine kidney cells. Lysis experiments with the Madin-Darby canine kidney cells indicated that most of the vinculin was soluble in Triton X-100, although some was found associated with the insoluble cytoskeletal residue. By immunofluorescence, vinculin in WI38 cells was localized to adhesion plaques as described by others. Discrete localization in platelets was also detected and appeared to depend on their state of adhesion and spreading. The results of these experiments suggest that human platelets contain a protein similar to vinculin. It is not clear if platelet vinculin is associated with structures analogous to adhesion plaques found in other cell types. The data indicate that the previously reported effects of nonmuscle vinculins on actin polymerization may be due to a contaminant or contaminants.
Assuntos
Plaquetas/análise , Proteínas Musculares/sangue , Actinas , Especificidade de Anticorpos , Células Cultivadas , Reações Cruzadas , Citoesqueleto/análise , Humanos , Peso Molecular , Proteínas Musculares/imunologia , Vinculina , ViscosidadeRESUMO
To determine the relative importance of CCK-A, CCK-B, and opioid receptors in mediating the antinociceptive actions of cholecystokinin, we evaluated the actions of selective agonists and antagonists in the mouse hot plate assay. The agonists used were CCK (1-30 nmol i.c.v.), a CCK-A receptor agonist (SNF9019; 0.3-10 nmol i.c.v.), and a CCK-B receptor agonist (SNF9007; 0.3-10 nmol i.c.v.). The antagonists used were the CCK-A receptor antagonist, L364,718 (12.5 nmol i.c.v.), CCK-B receptor antagonist, L365,260 (2.5-25 nmol i.c.v.), and the nonselective opioid receptor antagonist naloxone (1 mg/kg s.c.). CCK and its receptor-selective analogues, SNF9019 and SNF9007, resulted in antinociception that was blocked by naloxone, but was not antagonized by L364,718 or L365,260. In contrast, in positive control experiments, the inhibitory effects of CCK, SNF9019, and SNF9007 on gastrointestinal propulsion in mice were antagonized by identical i.c.v. doses of L364,718 and L365,260. We conclude that centrally administered CCK produces antinociception in the mouse hot plate assay via opioid receptors, but independent of CCK-A or CCK-B receptors. It is necessary to speculate that other CCK receptors, not antagonized by currently available selective antagonists, may exist.
Assuntos
Analgésicos/farmacologia , Colecistocinina/farmacologia , Receptores da Colecistocinina/antagonistas & inibidores , Analgesia , Analgésicos/antagonistas & inibidores , Animais , Trânsito Gastrointestinal/efeitos dos fármacos , Masculino , Camundongos , Camundongos Endogâmicos ICR , Receptor de Colecistocinina A , Receptor de Colecistocinina BRESUMO
The effect of the cholecystokininB (CCKB) receptor-selective cholecystokinin octapeptide (CCK-8) analog SNF 9007 on forskolin-stimulated adenylyl cyclase activity in NG108-15 hybrid cells was measured. The activity of SNF 9007 was compared to the delta opioid agonists D-Pen2-D-Pen5-enkephalin (DPDPE, delta 1 receptor-selective) and Tyr-D-Ala-Phe-Glu-Val-Val-Gly-NH2, (D-Ala2-deltorphin II, delta 2-receptor-selective) because SNF 9007 binds with moderate affinity to delta opioid receptors. SNF 9007 inhibited forskolin-stimulated adenylyl cyclase activity with efficacy similar to DPDPE. IC50 determinations showed that D-Ala2-deltorphin II was the most potent, followed by DPDPE, then SNF 9007 (IC50 values = 0.013, 0.21 and 4.8 microM, respectively). CCK-8 had no effect on adenylyl cyclase activity. The delta 1 receptor-selective antagonist 7-benzylidenenaltrexone hydrochloride (BNTX, 10 nM) had no effect on the activity of any of these agonists, but the delta 2 receptor-selective antagonist naltriben methanesulfonate (NTB, 10 nM) increased IC50 values of all the agonists. Combinations of BNTX and NTB (10 nM each) increased the D-Ala2-deltorphin II IC50 value 12-fold, the DPDPE IC50 value 18-fold and the SNF 9007 IC50 value 26-fold. The effect of the combined delta antagonists on SNF 9007 activity was different from the effect on DPDPE or D-Ala2-deltorphin II activity. These data suggest that the interaction of the CCK-8 analog SNF 9007 with opioid receptors in NG108-15 hybrid cells is different from the interaction of opioid peptides with these receptors.
Assuntos
Inibidores de Adenilil Ciclases , Analgésicos/farmacologia , Colecistocinina/análogos & derivados , Inibidores Enzimáticos/farmacologia , Dor/fisiopatologia , Fragmentos de Peptídeos/farmacologia , Sequência de Aminoácidos , Colecistocinina/farmacologia , D-Penicilina (2,5)-Encefalina , Encefalinas/farmacologia , Glioma , Células Híbridas/efeitos dos fármacos , Dados de Sequência Molecular , Neuroblastoma , Oligopeptídeos/farmacologia , Receptores Opioides delta/agonistasRESUMO
Carbamylcholine-stimulated potentiation of dibutyryl cyclic AMP-induced acid secretion by isolated rat parietal cells was specifically inhibited by the muscarinic cholinergic antagonist pirenzepine at an IC50 of 1.1 microM. In contrast to the weak inhibition by pirenzepine, the potentiation was inhibited by atropine at an IC50 of 4.6 nM. In vivo, pirenzepine is one-tenth as potent as atropine as an inhibitor of acid secretion. The weak activity of pirenzepine shown in this study suggests that its in vivo inhibitory activity is likely due to an interaction with a site involved in the regulation of gastric acid secretion which has higher-affinity muscarinic receptors for pirenzepine than those associated with parietal cells.
Assuntos
Benzodiazepinonas/farmacologia , Ácido Gástrico/metabolismo , Mucosa Gástrica/efeitos dos fármacos , 1-Metil-3-Isobutilxantina/farmacologia , Animais , Atropina/farmacologia , Bucladesina/farmacologia , Carbacol/farmacologia , Histamina/farmacologia , Técnicas In Vitro , Pirenzepina , RatosRESUMO
At some medical schools broader definitions of scholarship have emerged along with corresponding changes in their academic reward systems. Such situations are not common, however. The definition of scholarship generally applied by medical schools is unnecessarily narrow and excludes areas of legitimate academic activity and productivity that are vital to the fulfillment of the school's educational mission. The authors maintain that creative teaching with effectiveness that is rigorously substantiated, educational leadership with results that are demonstrable and broadly felt, and educational methods that advance learners' knowledge are consistent with the traditional definition of scholarship. Faculty whose educational activities fulfill the criteria above are scholars and must be recognized by promotion. The authors specifically address scholarship in education, focusing on teaching and other learning-related activities rather than on educational research, which may be assessed and rewarded using the same forms of evidence as basic science or clinical research. They build on Boyer's work, which provides a vocabulary for discussing the assumptions and values that underlie the roles of faculty as academicians. Next, they apply Glassick et al.'s criteria for judging scholarly work to faculty members' educational activities to establish a basis for recognition and reward consistent with those given for other forms of scholarship. Finally, the authors outline the organizational infrastructure needed to support scholars in education.
Assuntos
Docentes de Medicina , Faculdades de Medicina , Ensino/normas , Educação MédicaAssuntos
Temperatura Corporal/efeitos dos fármacos , Morfina/farmacologia , Neurotransmissores/fisiologia , Animais , Depressão Química , Dopamina/farmacologia , Haloperidol/farmacologia , Masculino , Metisergida/farmacologia , Norepinefrina/farmacologia , Fentolamina/farmacologia , Ratos , Serotonina/farmacologia , Fatores de TempoAssuntos
Suco Gástrico/metabolismo , Mucosa Gástrica/fisiologia , Receptores Histamínicos H2/fisiologia , Receptores Histamínicos/fisiologia , Acetilcolina/antagonistas & inibidores , Animais , Antagonistas dos Receptores H2 da Histamina/farmacologia , Humanos , Pentagastrina/fisiologia , Receptores Histamínicos H2/efeitos dos fármacosAssuntos
Acetilcolina/farmacologia , Carbacol/farmacologia , Mucosa Gástrica/fisiologia , Aminopirina/metabolismo , Animais , Atropina/farmacologia , Transporte Biológico/efeitos dos fármacos , Relação Dose-Resposta a Droga , Mucosa Gástrica/citologia , Mucosa Gástrica/efeitos dos fármacos , Técnicas In Vitro , Cloreto de Metacolina , Compostos de Metacolina/farmacologia , Oxotremorina/farmacologia , RatosRESUMO
Prostaglandin E2 (PGE2) differentially inhibited histamine and isoproterenol stimulation of [14C]aminopyrine accumulation in rat parietal cell preparations. Low concentrations of PGE2 decreased the maximum response to isoproterenol whereas higher concentrations increased the EC50 of histamine with only a modest effect on the maximum response. Also, PGE2 potentiated dibutyryl cyclic AMP stimulation of aminopyrine accumulation in either the absence or presence of carbachol. In contrast, PGE2 inhibited potentiation between carbachol and histamine due to its inhibitory effect on histamine and possibly also to an inhibitory effect on cholinergic activity. Islet activating protein prevented the inhibitory actions of PGE2. To account for these results a model is presented based on the recent proposal by Gilman (Cell 36: 577-579, 1984) of an interaction between components of adenylyl cyclase stimulatory and inhibitory guanine nucleotide binding proteins.
Assuntos
Aminopirina/metabolismo , Células Parietais Gástricas/efeitos dos fármacos , Prostaglandinas E/farmacologia , Toxina Adenilato Ciclase , Inibidores de Adenilil Ciclases , Animais , Bucladesina/farmacologia , Radioisótopos de Carbono , Colforsina/farmacologia , Dinoprostona , Relação Dose-Resposta a Droga , Proteínas de Ligação ao GTP/metabolismo , Histamina/farmacologia , Técnicas In Vitro , Isoproterenol/farmacologia , Masculino , Modelos Biológicos , Sistema Nervoso Parassimpático/efeitos dos fármacos , Células Parietais Gástricas/metabolismo , Toxina Pertussis , Ratos , Ratos Endogâmicos , Fatores de Virulência de Bordetella/farmacologiaRESUMO
Isoproterenol (Iso), epinephrine and norepinephrine each stimulated isolated gastric mucosal parietal cells as shown by an increased accumulation of [14C]aminopyrine (AP), an indirect measure of acid secretion. The beta receptor selective agonists metaproterenol, terbutaline and zinterol stimulated AP accumulation to the same extent as Iso, whereas the beta-1 receptor selective agonist dobutamine was only 20% as effective. The general beta receptor antagonists oxprenolol and dl-propranolol and the beta-2 receptor antagonist H35/25 inhibited Iso-stimulated AP accumulation. Receptor stereoselectivity was shown by the approximately 100-fold difference in potency of the I- and d-isomers of propranolol. The alpha receptor antagonists phentolamine and phenoxybenzamine, the beta-1 receptor antagonists metoprolol and practolol and the muscarinic receptor antagonist atropine were without effect. The histamine H2-receptor antagonist cimetidine inhibited Iso-stimulated AP accumulation an average of 40% at a concentration which inhibits completely histamine-stimulated AP accumulation. The data demonstrate that cells of the rat gastric mucosa have adrenergic beta-2 receptors which when stimulated result in an increase in acid secretion. The results also show that the response is in part mediated indirectly by catecholamine-stimulated release of histamine.
Assuntos
Mucosa Gástrica/citologia , Receptores Adrenérgicos beta/metabolismo , 1-Metil-3-Isobutilxantina/farmacologia , Agonistas Adrenérgicos beta/farmacologia , Aminopirina/metabolismo , Animais , Atropina/farmacologia , Cimetidina/farmacologia , Mucosa Gástrica/metabolismo , Histamina/farmacologia , Isoproterenol/farmacologia , Masculino , Ratos , Ratos EndogâmicosRESUMO
The time course for the development and disappearance fo tolerance to the hypothermic effects of morphine was determined after a single subcutaneous injection (10 mg/kg) in rats. Body temperature responses to second injections, given at varying times after the first, were compared with those produced by the initial injections. Tolerance (attenuation of the hypothermic response) induced by a single dose of morphine was found to be biphasic. Acute tolerance was apparent by 4.5 hours and lasted at least 20 hours after morphine administration. Development of long-term tolerance occurred within 24 hours, was maximal at 3 days and persisted up to 11 days. Both acute and long-term tolerance were drug specific since hypothermic responses to pentobarbital were not altered either 4.5 or 72 hours after morphine. Long-term tolerance was attenuated by co-administration of naloxone with initial dose of morphine. Long-term tolerance induced by multiple doses of morphine (300 mg/kg/day) differed from that induced by a single dose in persistence (3-4 weeks) rather than in quality or magnitude. The thermoregulatory response of the rat provides a sensitive measurement system which allows discrimination between acute and long-term opiate effects.
Assuntos
Temperatura Corporal/efeitos dos fármacos , Morfina/farmacologia , Animais , Depressão Química , Interações Medicamentosas , Tolerância a Medicamentos , Humanos , Injeções Subcutâneas , Masculino , Morfina/administração & dosagem , Dependência de Morfina/fisiopatologia , Pentobarbital/farmacologia , Ratos , Receptores Opioides/fisiologia , Fatores de TempoRESUMO
Limited proteolysis, affinity chromatography, and immunoblotting have been used to define the domains of chicken gizzard caldesmon, caldesmon120, that interact with calmodulin, F-actin, and a monoclonal antibody prepared using human platelet caldesmon. Treatment of caldesmon120 with chymotrypsin produces groups of fragments near 100, 80, 60, 38, and 20 kDa. Further digestion produces peptides between 40 and 50 kDa. The 100- and 80-kDa peptides cross-react with the monoclonal antibody; the smaller polypeptides do not. The kinetics of cleavage and the antibody studies indicate that the 38- and 80-kDa fragments are the two major pieces of the 120-kDa protein. The 38-kDa fragment, purified by high performance liquid chromatography, and several of its subfragments at 21 and 25 kDa sediment with F-actin, bind to calmodulin-Sepharose in the presence of Ca2+, and are displaced from F-actin by Ca2+-calmodulin. The 80-kDa fragments did not interact with F-actin or calmodulin. We have tentatively placed the 38-kDa fragment at the C-terminal using polyclonal antibodies selected against a beta-galactosidase-caldesmon120 fusion protein produced by a lambda gt11 lysogen. The 38-, 25-, and 21-kDa fragments cross-react with these antibodies; the 80- and 60-kDa fragments do not. Caldesmon77 from human platelets also cross-reacts with these selected antibodies. The results suggest that interacting calmodulin and F-actin binding sites are localized on a 38-kDa C-terminal fragment of caldesmon. The smallest subfragment of this peptide that binds to both F-actin and calmodulin-Sepharose is about 21 kDa. The monoclonal antibody epitope is tentatively localized near the N-terminal of caldesmon77 and must be within 50 kDa of the N-terminal on caldesmon120.
Assuntos
Proteínas de Ligação a Calmodulina/análise , Moela das Aves/análise , Animais , Anticorpos Monoclonais , Sítios de Ligação , Galinhas , Cromatografia de Afinidade , Quimotripsina/metabolismo , Reações Cruzadas , Epitopos/análise , Técnicas de Imunoadsorção , Peso Molecular , Fragmentos de Peptídeos/análise , Subtilisinas/metabolismo , Tripsina/metabolismoRESUMO
The 600 x g particulate fraction of gastric mucosal scrapings from rats was incubated with 3H-metiamide which saturated available binding sites at a concentration of 1 muM. Scatchard plots showed a single component with a Kd value of 0.2 muM. Unlabelled cimetidine and histamine competed with 3H-metiamide binding. The 600 x g particulate fraction also contained all of the hormone and sodium fluoride sensitive adenylyl cyclase. Adenylyl cyclase activity was not altered by histamine, pentagastrin or carbachol but was increased during incubation with prostaglandin E1, secretin and epinephrine. These findings do not support the hypthesis that gastric secretion is mediated by intracellular accumulation of cyclic AMP.
Assuntos
AMP Cíclico/fisiologia , Suco Gástrico/metabolismo , Mucosa Gástrica/efeitos dos fármacos , Histamina/farmacologia , 3',5'-AMP Cíclico Fosfodiesterases/farmacologia , Adenilil Ciclases/metabolismo , Adenilil Ciclases/farmacologia , Animais , Ativação Enzimática , Feminino , Mucosa Gástrica/enzimologia , Mucosa Gástrica/metabolismo , Metiamida/metabolismo , Ratos , Receptores de Droga/efeitos dos fármacos , Estimulação QuímicaRESUMO
Submicrogram concentrations (0.04-0.29 microM) of the microfilament disrupting agents cytochalasins D, E, and B (CD, CE, CB) were shown to inhibit secretagogue-stimulated 14C-aminopyrine accumulation (AP) in isolated rat gastric mucosal parietal cells. The microtubule disrupting agent colchicine had little influence on AP accumulation. Histamine- and dibutyryl cyclic AMP (DbcAMP)-stimulated AP accumulation was inhibited with an order of potency CD greater than CE approximately equal to CB. CB inhibition of these secretagogue actions was, however, only approximately 65-70% of the maximal stimulated response, whereas CD and CE caused 100% inhibition. On the other hand, carbamylcholine-stimulated AP accumulation was inhibited 100% by all cytochalasins tested with an order of potency CD approximately equal to CE greater than CB. These data are discussed in relation to acid secretagogue-induced morphological changes involving actin filament organization in parietal cells.
Assuntos
Citocalasinas/farmacologia , Mucosa Gástrica/efeitos dos fármacos , Actinas/fisiologia , Animais , Bucladesina/antagonistas & inibidores , Carbacol/antagonistas & inibidores , Relação Dose-Resposta a Droga , Suco Gástrico/metabolismo , Antagonistas dos Receptores Histamínicos , Concentração de Íons de Hidrogênio , Ratos , Taxa Secretória/efeitos dos fármacosRESUMO
Rat gastric parietal cells were isolated to 90% or greater purity by discontinuous gradient ultracentrifugation in sucrose-Ficoll. Adenylyl cyclase activity was initiated by histamine in the presence of 5'-guanylyl imidodiphosphate, but not by pentagastrin or acetylcholine. The concentration of histamine needed for half-maximal activation of adenylyl cyclase was 38 microM. The histamine H2-receptor antagonist, metiamide, inhibited histamine (100 microM) activation with a Ki of 0.9 microM. The effects of other histamine agonists and antagonists suggest that presence of H2-type histaminic receptors on parietal cells. Adenylyl cyclase activity was also stimulated by isoproterenol, norepinephrine, and epinephrine, but not by methoxamine. Half-maximal activation by isoproterenol occurred at 0.5 microM. Propranolol, but not phentolamine, prevented activation by these agents, indicating the presence of beta-adrenergic receptors on parietal cells. Prostaglandins E2 stimulated adenylyl cyclase of partially purified (30%), but not the enriched (90%), parietal cell populations.
Assuntos
Adenilil Ciclases/metabolismo , Mucosa Gástrica/enzimologia , Histamina/fisiologia , Animais , Feminino , Mucosa Gástrica/citologia , Mucosa Gástrica/efeitos dos fármacos , Liberação de Histamina/efeitos dos fármacos , Masculino , Prostaglandinas E/farmacologia , Ratos , Simpatomiméticos/farmacologiaRESUMO
Isolated, partially purified or enriched rat gastric mucosal parietal cells were shown to respond to histamine and other histaminic H2-receptor agonists as measured by an increased accumulation of [14C]aminopyrine. The response was temperature-dependent, related to parietal cell purity and inhibited selectively and reversibly by H2-receptor antagonists. H1-receptor antagonists noncompetitively inhibited histamine, carbamylcholine and dibutyryl cyclic AMP-stimulated aminopyrine accumulation. The affinity constants calculated for the H2-receptor agonists and antagonists were similar to those previously determined in the studies of activation and inhibition of adenylyl cyclase in enriched parietal cell preparations. The results strongly suggest that a correlation exists between the ability of histamine and its analogs to stimulate isolated rat parietal cell function and their ability to stimulate adenylyl cyclase activity. Potentiation of aminopyrine accumulation in the presence of histamine and carbamylcholine is due to specific receptor effects of each secretagogue.
Assuntos
Mucosa Gástrica/citologia , Histamina/farmacologia , Aminopirina/metabolismo , Animais , Separação Celular , Feminino , Mucosa Gástrica/efeitos dos fármacos , Mucosa Gástrica/metabolismo , Histamina/análogos & derivados , Antagonistas dos Receptores Histamínicos H1/farmacologia , Antagonistas dos Receptores H2 da Histamina/farmacologia , Técnicas In Vitro , Ratos , Ratos EndogâmicosRESUMO
A rapidly-labeled RNA fraction can be isolated from hen oviduct polysomes that has characteristics of the messenger RNA (mRNA) for the cell-specific protein, ovalbumin. This RNA, which sediments in the 8-17S region of sucrose gradients, possesses properties suggestive of the presence of a polyadenylic acid sequence and can be translated with fidelity in a cell-free protein synthesizing system derived from rabbit reticulocytes. The identity of the protein product as ovalbumin is confirmed by three methods, and translation of ovalbumin mRNA is shown to be dependent both on amount of exogenous mRNA and incubation time. Both rate and extent of ovalbumin synthesis is enhanced by the addition of a protein extract from ribosomes that contains peptide chain initiation factors. Finally, the presence of this specific mRNA is shown to be estrogen-dependent: it is induced by estrogen administration to immature chicks, disappears upon cessation of estrogen treatment, and can be reinduced by a single injection of estrogen to chicks that have been pretreated with estrogen and then withdrawn from the hormone.
Assuntos
Estrogênios/farmacologia , Ovalbumina/biossíntese , Oviductos/análise , RNA Mensageiro , Acrilamidas , Animais , Reações Antígeno-Anticorpo , Centrifugação com Gradiente de Concentração , Galinhas , Eletroforese , Feminino , Código Genético , Soros Imunes , Ovalbumina/metabolismo , Oviductos/efeitos dos fármacos , Oviductos/metabolismo , Iniciação Traducional da Cadeia Peptídica/efeitos dos fármacos , RNA Mensageiro/metabolismo , Ribossomos/análise , Soroalbumina Bovina , Dodecilsulfato de SódioRESUMO
There has been no previous demonstration of opioid tolerance and dependence with respect to the propulsive and contractile activities of the gut in vivo. In the experiments described herein, morphine was administered continuously (1 mg/kg/hr s.c., 72 hr) and/or by bolus injection (2 mg/kg) and intestinal motility and transit were evaluated in unanesthetized rats. Tolerance in intestinal motility (contractions) and propulsion (transit) was measured in two ways, i.e., by measuring the time required for motility and propulsion to return to control values and by measuring the loss of effectiveness of bolus morphine administered to animals receiving continuous infusion of the opiate. The dose of morphine chosen for continuous administration (1 mg/kg/hr s.c. via Alzet minipumps) was based on the dose at which morphine inhibited intestinal propulsion by 50%. Morphine (1 mg/kg/hr) decreased the frequency of contractions in, and propulsion along, the small bowel and colon and produced mild antinociception. The frequency of duodenal and colonic contractions returned to normal within 13 to 16 hr. After 24 hr of morphine treatment, the inhibitory effects of bolus doses of morphine on motility and transit were diminished; the effects were eventually lost (48 hr). Similarly, the antinociceptive effects of bolus doses of morphine were diminished by 18 hr and lost by 24 hr. Naloxone (0.1 mg/kg s.c.) given to morphine-tolerant animals (72 hr) resulted in an increase in the frequency and amplitude of contractions in the colon, an increase in the propulsive activity of the small intestine and colon and diarrhea. These results provide direct demonstration of opioid tolerance and dependence of contractile and propulsive activity in the rat intestine in vivo.
Assuntos
Motilidade Gastrointestinal/efeitos dos fármacos , Trânsito Gastrointestinal/efeitos dos fármacos , Dependência de Morfina/fisiopatologia , Morfina/farmacologia , Dor , Animais , Colo , Tolerância a Medicamentos , Duodeno , Infusões Parenterais , Injeções Subcutâneas , Masculino , Morfina/administração & dosagem , Músculo Liso/efeitos dos fármacos , Músculo Liso/fisiopatologia , Naloxona/farmacologia , Ratos , Ratos Sprague-Dawley , Comportamento Estereotipado/efeitos dos fármacosRESUMO
Estrogen-induced morphologic differentiation of chick oviduct is accompanied by increases in the total endogenous mRNA activity of oviduct polysomes. Concomitant increases are also noted in ribosome translational capacity and activity of peptide chain initiation factors. Once the differentiation process nears completion (about 7 days of estrogen administration), total ribosomebound mRNA activity decreases, but the translational machinery remains very active. In addition, estrogen induces the accumulation of ovalbumin mRNA before ovalbumin is demonstrable in the oviduct. The data suggest that the rate-limiting event in the hormonal induction of cell-specific proteins, such as ovalbumin, is the synthesis and intracellular accumulation of specific mRNA for such proteins.
Assuntos
Dietilestilbestrol/farmacologia , Ovalbumina/biossíntese , Oviductos/crescimento & desenvolvimento , Biossíntese de Proteínas , RNA Mensageiro/metabolismo , Animais , Isótopos de Carbono , Feminino , Cinética , Oviductos/citologia , Oviductos/efeitos dos fármacos , Oviductos/metabolismo , Iniciação Traducional da Cadeia Peptídica , Fenilalanina/metabolismo , Polinucleotídeos/farmacologia , RNA Mensageiro/farmacologia , RNA de Transferência/metabolismo , Coelhos , Reticulócitos/efeitos dos fármacos , Reticulócitos/metabolismo , Ribossomos/efeitos dos fármacos , Ribossomos/metabolismo , Nucleotídeos de Uracila/farmacologia , Valina/metabolismoRESUMO
Prostaglandin (PG) E1, E2, A1, and A2 stimulated rat gastric corpus mucosal membrane adenylyl cyclase activity. PGE1 (Kalpha congruent to 8 muM) affected the maximum velocity but not the affinity of the enzyme for ATP and maximum PGE1 activation was not affected by histamine H1 or H2 receptor antagonists. 5'-Guanylyl-diphosphoimide (Gpp(NH)p), but not GTP, stimulated both the basal and PGE1-stimulated adenylyl cyclase activities, although the percentage stimulation by maximal PGE was the same with or without Gpp(NH)p. NaF stimulation was also additive to that of PGE1. Secretin also stimulated gastric mucosal adenylyl cyclase activity (Kalpha congruent to 30 nM). Maximal secretin activation was not additive to that of PGE1, suggesting a coupling to the same adenylyl cyclase catalytic site. These studies suggest that mucosal membranes may contain beta-adrenergic receptors. The adenylyl cyclase activating agents used in this study, PGE1, secretin, and the catecholamines, are all known inhibitors of gastric acid secretion, suggesting a possible involvement of cyclic AMP in the inhibition of acid secretion in the rat stomach.